Format

Send to

Choose Destination
Front Immunol. 2017 May 15;8:555. doi: 10.3389/fimmu.2017.00555. eCollection 2017.

Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives.

Guo ZS1,2, Liu Z1,2, Kowalsky S1,2, Feist M1,2,3, Kalinski P1,2,4, Lu B1,4, Storkus WJ1,4,5, Bartlett DL1,2.

Author information

1
University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
2
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
3
Department of Surgery, CCM/CVK, Charité - Universitaetsmedizin Berlin, Berlin, Germany.
4
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
5
Department of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Abstract

The concept of oncolytic virus (OV)-mediated cancer therapy has been shifted from an operational virotherapy paradigm to an immunotherapy. OVs often induce immunogenic cell death (ICD) of cancer cells, and they may interact directly with immune cells as well to prime antitumor immunity. We and others have developed a number of strategies to further stimulate antitumor immunity and to productively modulate the tumor microenvironment (TME) for potent and sustained antitumor immune cell activity. First, OVs have been engineered or combined with other ICD inducers to promote more effective T cell cross-priming, and in many cases, the breaking of functional immune tolerance. Second, OVs may be armed to express Th1-stimulatory cytokines/chemokines or costimulators to recruit and sustain the potent antitumor immunity into the TME to focus their therapeutic activity within the sites of disease. Third, combinations of OV with immunomodulatory drugs or antibodies that recondition the TME have proven to be highly promising in early studies. Fourth, combinations of OVs with other immunotherapeutic regimens (such as prime-boost cancer vaccines, CAR T cells; armed with bispecific T-cell engagers) have also yielded promising preliminary findings. Finally, OVs have been combined with immune checkpoint blockade, with robust antitumor efficacy being observed in pilot evaluations. Despite some expected hurdles for the rapid translation of OV-based state-of-the-art protocols, we believe that a cohort of these novel approaches will join the repertoire of standard cancer treatment options in the near future.

KEYWORDS:

ICD inducer; T cells; antigen; antitumor immunity; combination; cross-presentation; immune checkpoint blockade; immunogenic cell death

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center